MCQs: Transdermal Drug Delivery System (TDDS)

Multiple Choice Questions on Transdermal Drug Delivery System

MCQs: Transdermal Drug Delivery System (TDDS)

Quiz

  

Atttempt as many times u like within 45 minutes.

 

1. The primary barrier for the TDDS is,
   1.   Dermis
   2.   Hypodermis
   3.   Subcutaneous Tissue
   4.   Epidermis
2. Well developed “intercellular lipid lamellae” is a feature of which layer of the epithelium.
   1.   Stratum basale
   2.   Stratum spinosum
   3.   Stratum lucidum
   4.   Stratum corneum
3. Which of the following route is commonly used for penetration of the drugs into skin,
   1.   Transcellular Route
   2.   Intercellular Route
   3.   Intracellular Route
   4.   Both A & B.
4. From which of the following anatomical structures the drugs from TDDS enters the systemic circulation.
   1.   Epidermis
   2.   Dermis
   3.   Sweat Glands / Hair follicles
   4.   Hypodermis
5. From which of the following mechanisms most of the drugs get absorbed via skin.
   1.   Active transport
   2.   Passive Transport
   3.   Facilitated transport
   4.   Osmosis
6. Which of the following is NOT an advantage of the TDDS.
   1.   Noninvasive
   2.   Avods GI tract
   3.   Larger doses can be administered
   4.   Useful for drugs with narrow therapeutic indices
7. Which of the following molecular weights is considered an ideal for the candidate of TDDS.
   1.   Not More Than 400 Dalton
   2.   Not More Than 600 Dalton
   3.   Not More Than 800 Dalton
   4.   Not More Than 1000 Dalton
8. Identify the component which is not a part of the Transdermal Patch.
   1.   Seal Coat.
   2.   Adhesive layer.
   3.   Backing membrane.
   4.   Polymer matrix.
9. Silicone is used as _____ in the Transdermal patch.
   1.   A backing membrane.
   2.   An adhesive.
   3.   A polymer.
   4.   A permeation enhancer.
10. Iontophoresis is used in TDDS as a,
    1.   Physical penetration enhancer.
    2.   Chemical penetration enhancer.
    3.   Drug Carrier.
    4.   Polymer matrix.
11. Which of the following is not associated with TDDS as a side effect,
    1.   Urticaria
    2.   Erythema
    3.   Contact dermatitis
    4.   Hyperchlorhydria
12. Azone TS & SRPA are used in TDDS as,
    1.   Drug Carrier.
    2.   Polymer matrix.
    3.   Penetration enhancer.
    4.   Adhesive.
13. Which of the following statements is true with effect of “Skin Thickness” on rate of permeation.
    1.   Rate of permeation is not dependent on thickness of the skin.
    2.   Rate of permeation increases with an increase in skin thickness.
    3.   Rate of permeation decreases with an increase in skin thickness.
    4.   Rate of permeation increases skin thickness.
14. Which of the following is not a candidate for TDDS.
    1.   Drugs with short half-lives
    2.   Drugs with narrow therapeutic indices
    3.   Easy removal and termination
    4.   Local healers for peptic ulcer
15. Identify the correct order of layers for “Microreservior Patch”.
    1.   Backing Membrane, Occlusive Base, Drug Microreservior, Release liners.
    2.   Backing Membrane, Drug Adhesive Mix, Release liners.
    3.   Backing Membrane, Controlled Release Membrane, Drug Microreservior, Release liners.
    4.   Occlusive Base, Drug Microreservior, Backing Membrane, Release liners.
16. The first drug used for TDDS was,
    1.   Cetirizine
    2.   Nicotine
    3.   Scopolamine
    4.   Fantanyl
17. Which of the following USP Dissolution Test Apparatuses is used to study drug release from TDDS.
    1.   Paddle over Disc ( Type 5)
    2.   Rotating Cylinder.
    3.   Basket Apparatus.
    4.   Both A & B.
18. Which of the following characteristics is suitable for selection of a candidate for TDDS?
    1.   Large Dose.
    2.   Larger molecular Size.
    3.   Higher first pass effect.
    4.   Metabolism in Skin.
19. Which of the following factors does not affect diffusion of the drug through stratum corneum?
    1.   Drug concentration.
    2.   Surface tension.
    3.   Partition coefficient of the drug.
    4.   Aqueous solubility of the drug.
20. The mechanism of chemical permeation enhancer is,
    1.   Cause deposition of penetrant in the stratum corneum.
    2.   Alters physicochemical properties of stratum corneum.
    3.   Causes reversible damage to the stratum corneum.
    4.   Both b & c.